Abeona Therapeutics Inc. (NASDAQ: ABEO) is a Healthcare company (Biotechnology) with a market capitalization of $149M. The Maz Rating grades it against the other companies in its sector.
Abeona Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.60, Abeona Therapeutics Inc. trades at 3.8x sales and 1.2x book value. Over the last twelve months it generated about $39M of revenue and a net loss of $65M. It runs a gross margin of 58.2%, an operating margin of -186.1% and a net margin of -160.3%. It shows return on equity of -44.8%, return on invested capital of -46.0% and a free cash flow yield of -44.7%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 5.69. Over the past 52 weeks the share price ranged from $2.09 to $7.65, with a beta of 1.30.
Abeona Therapeutics Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Abeona Therapeutics Inc. (ABEO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.22% / 30% · (Cash+Inv) / Mkt Cap (36m) 48.1% / 30% · Interest income / Revenue 16.8% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 4.22% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 48.1% / 33% · Receivables / Mkt Cap (36m) 5.78% / 49% · Interest income / Revenue 16.8% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 4.22% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 48.1% / 33.33% · Receivables / Mkt Cap (24m) 5.78% / 33.33% · Interest income / Revenue 16.8% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 8.44% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 83.4% / 33.33% · Receivables / Avg Assets (4Q) 5.14% / 33.33% · Interest income / Revenue 16.8% / 5% | Fail |
| FTSE | Debt / Total Assets 6.89% / 33.33% · (Cash+ST Inv) / Total Assets 78.5% / 33.33% · (Cash+Recv) / Total Assets 87.9% / 33.33% · Interest income / Revenue 16.8% / 5% | Fail |
No. As of September 2026, Abeona Therapeutics Inc. (ABEO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Abeona Therapeutics Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 16.8% of each dividend: Abeona Therapeutics Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.